X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
indacaterol/glycopyrronium (32) 32
chronic obstructive pulmonary disease (27) 27
indacaterol (27) 27
index medicus (27) 27
respiratory system (22) 22
glycopyrronium (21) 21
humans (20) 20
obstructive pulmonary-disease (20) 20
pulmonary disease, chronic obstructive - drug therapy (18) 18
copd (17) 17
lung diseases, obstructive (17) 17
tiotropium (17) 17
female (15) 15
glycopyrrolate - administration & dosage (15) 15
male (15) 15
double-blind (14) 14
indans - administration & dosage (14) 14
quinolones - administration & dosage (14) 14
bronchodilator agents - administration & dosage (13) 13
treatment outcome (13) 13
qva149 (12) 12
adrenergic beta-2 receptor agonists - administration & dosage (11) 11
aged (11) 11
muscarinic antagonists - administration & dosage (11) 11
adrenergic beta-2 receptor agonists - adverse effects (10) 10
diseases of the respiratory system (10) 10
middle aged (10) 10
bronchodilator agents - adverse effects (9) 9
forced expiratory volume (9) 9
muscarinic antagonists - adverse effects (9) 9
pulmonary disease, chronic obstructive - diagnosis (9) 9
salmeterol-fluticasone (9) 9
administration, inhalation (8) 8
disease progression (8) 8
glycopyrrolate - adverse effects (8) 8
original research (8) 8
parallel-group (8) 8
drug therapy (7) 7
indans - adverse effects (7) 7
inhaled corticosteroids (7) 7
lung - drug effects (7) 7
lung - physiopathology (7) 7
pulmonary disease, chronic obstructive - physiopathology (7) 7
quinolones - adverse effects (7) 7
research (7) 7
salmeterol/fluticasone (7) 7
time factors (7) 7
care and treatment (6) 6
double-blind method (6) 6
drug combinations (6) 6
dyspnea (6) 6
exacerbation (6) 6
exacerbations (6) 6
fluticasone (6) 6
fluticasone-salmeterol drug combination - administration & dosage (6) 6
international journal of chronic obstructive pulmonary disease (6) 6
mortality (6) 6
pharmacology & pharmacy (6) 6
quality of life (6) 6
salmeterol (6) 6
severity of illness index (6) 6
adult (5) 5
analysis (5) 5
clinical trials (5) 5
dosage and administration (5) 5
drug therapy, combination (5) 5
dual bronchodilation (5) 5
efficacy (5) 5
laba (5) 5
lung diseases (5) 5
lung-function (5) 5
prevention (5) 5
respiratory tract diseases (5) 5
risk (5) 5
safety (5) 5
bronchodilator agents (4) 4
cost-effective (4) 4
development and progression (4) 4
drug administration schedule (4) 4
fixed-dose combination (4) 4
health status (4) 4
lung function (4) 4
medical research (4) 4
medicine, general & internal (4) 4
obstructive lung disease (4) 4
patients (4) 4
recovery of function (4) 4
surveys and questionnaires (4) 4
vital capacity (4) 4
adrenal cortex hormones - administration & dosage (3) 3
adrenergic beta-2 receptor agonists - therapeutic use (3) 3
asian continental ancestry group (3) 3
bronchodilator agents - therapeutic use (3) 3
case report (3) 3
clinical medicine (3) 3
combination (3) 3
comparative analysis (3) 3
complications and side effects (3) 3
corticosteroids (3) 3
cost-benefit analysis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 08/2018, Volume 379, Issue 6, pp. 591 - 591
Journal Article
Respiration, ISSN 0025-7931, 04/2018, Volume 95, Issue Suppl 1, pp. 6 - 10
We present the case of a 77-year-old man diagnosed with chronic obstructive pulmonary disease (COPD) stage D with emphysema phenotype and treated with triple... 
Case Report | Chronic obstructive pulmonary disease | GOLD stage | Ventilatory response to exercise | Indacaterol/ glycopyrronium | MILD | Indacaterol/glycopyrronium | DIAGNOSIS | MANAGEMENT | RESPIRATORY SYSTEM | CONSTRAINTS | EXERCISE | COPD | Tiotropium | Medical research | Lung diseases, Obstructive | Medicine, Experimental | Development and progression | Indacaterol | Fluticasone
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 08/2018, Volume 198, Issue 3, pp. 329 - 339
Journal Article
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2017, Volume 2018, Issue 2, p. CD012066
Journal Article
Advances in Therapy, ISSN 0741-238X, 3/2019, Volume 36, Issue 3, pp. 495 - 519
Maintenance bronchodilator therapy with long-acting β-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) is the cornerstone treatment for patients... 
Indacaterol/glycopyrronium | Rheumatology | Internal Medicine | Oncology | Olodaterol/tiotropium | Medicine & Public Health | Asia | Fixed-dose combination | Formoterol/aclidinium | Vilanterol/umeclidinium | Long-acting muscarinic antagonists | Long-acting β-agonists | Chronic obstructive pulmonary disease | Cardiology | Pharmacology/Toxicology | Endocrinology | MEDICINE, RESEARCH & EXPERIMENTAL | Long-acting beta-agonists | PHARMACOLOGICAL CHARACTERIZATION | QVA149 INDACATEROL/GLYCOPYRRONIUM | OBSTRUCTIVE PULMONARY-DISEASE | ACLIDINIUM BROMIDE | 5 MU-G | ONCE-DAILY INDACATEROL | TWICE-DAILY SALMETEROL | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | JAPANESE PATIENTS | CHINESE PATIENTS | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Muscarinic Antagonists - adverse effects | Muscarinic Antagonists - therapeutic use | Benzyl Alcohols - therapeutic use | Indans - therapeutic use | Quinuclidines - therapeutic use | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Tiotropium Bromide - therapeutic use | Bronchodilator Agents - adverse effects | Formoterol Fumarate - therapeutic use | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Tropanes - therapeutic use | Benzoxazines - therapeutic use | Muscarinic Antagonists - administration & dosage | Asian Continental Ancestry Group | Chlorobenzenes - therapeutic use | Adrenergic beta-2 Receptor Agonists - administration & dosage | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | aclidinium | umeclidinium | Indacaterol | Review | tiotropium | Vilanterol | Formoterol | glycopyrronium | Olodaterol
Journal Article
International Journal of COPD, ISSN 1176-9106, 04/2018, Volume 13, pp. 1079 - 1088
Objective: The aim of this study was to evaluate the cost-effectiveness of the long-acting beta-2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual... 
LABA/LAMA dual bronchodilator | Indacaterol/glycopyrronium | ICS/LABA combination | Maintenance therapy | Cost-effectiveness | COPD | cost-effectiveness | DUAL BRONCHODILATOR INDACATEROL/GLYCOPYRRONIUM | LUNG-FUNCTION | QVA149 | maintenance therapy | REFERENCE VALUES | OBSTRUCTIVE PULMONARY-DISEASE | FLUTICASONE PROPIONATE | FORCED SPIROMETRY | RESPIRATORY SYSTEM | PARALLEL-GROUP | DOUBLE-BLIND | HEALTH | indacaterol/glycopyrronium | Drug Costs | Indans - adverse effects | Quinolones - economics | Muscarinic Antagonists - economics | Bronchodilator Agents - administration & dosage | Humans | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Models, Economic | Indans - economics | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Computer Simulation | Adult | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Pulmonary Disease, Chronic Obstructive - economics | Glycopyrrolate - adverse effects | Quality-Adjusted Life Years | Severity of Illness Index | Bronchodilator Agents - economics | Pulmonary Disease, Chronic Obstructive - diagnosis | Glycopyrrolate - economics | Treatment Outcome | Lung - physiopathology | Disease Progression | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Adrenergic beta-2 Receptor Agonists - economics | Glycopyrrolate - administration & dosage | Cost-Benefit Analysis | Lung - drug effects | Taiwan | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium | Medical research | Lung diseases, Obstructive | Analysis | Economic aspects | Medicine, Experimental | Models | Indacaterol | Drug therapy, Combination | Cost benefit analysis | chronic obstructive pulmonary disease (COPD)
Journal Article
Respiration, ISSN 0025-7931, 04/2018, Volume 95, Issue Suppl 1, pp. 3 - 5
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, and it is associated with a high economic burden. Heart... 
Case Report | Heart failure | Indacaterol/glycopyrronium | Chronic obstructive pulmonary disease | UNITED-STATES | RESPIRATORY SYSTEM | ADULTS | COPD | Tiotropium | Care and treatment | Pantoprazole | Lung diseases | Cardiac patients | Mortality | Apixaban | Indacaterol
Journal Article
Respiration, ISSN 0025-7931, 04/2018, Volume 95, Issue Suppl 1, pp. 19 - 21
Chronic obstructive pulmonary disease is a highly prevalent disease, especially in the aging population, associated with several functional disabilities and a... 
Case Report | Indacaterol/glycopyrronium | Severe respiratory failure | Chronic obstructive pulmonary disease | INDACATEROL | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | LUNG HYPERINFLATION | COPD | Tiotropium | Lung diseases, Obstructive | Indacaterol | Respiratory insufficiency | Drug therapy
Journal Article
Multidisciplinary Respiratory Medicine, ISSN 1828-695X, 2014, Volume 9, Issue 1, pp. 50 - 50
The most recent guidelines define COPD in a multidimensional way, nevertheless the diagnosis is still linked to the limitation of airflow, usually measured by... 
Bronchodilation | Fixed combination indacaterol/glycopyrronium | Dyspnea | Hyperinflation | LABA | HRQoL | Exercise tolerance | LAMA | COPD | RESPIRATORY SYSTEM | Development and progression | Respiratory agents | Lung diseases, Obstructive | Care and treatment
Journal Article
Respiratory Research, ISSN 1465-9921, 07/2017, Volume 18, Issue 1, pp. 140 - 9
Background: Dual bronchodilation combining a long-acting beta(2)-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) is the preferred choice of... 
Indacaterol/glycopyrronium | Open-label | Chronic obstructive pulmonary disease | Dual bronchodilation | Direct switch | INDACATEROL | MULTICENTER | QVA149 | SALMETEROL-FLUTICASONE | SALMETEROL/FLUTICASONE | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | DOUBLE-BLIND | EXACERBATIONS | TIOTROPIUM | GLYCOPYRRONIUM | Indans - adverse effects | Prospective Studies | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Patient Safety | Adult | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Dyspnea - diagnosis | Europe | Risk Factors | Treatment Outcome | Dyspnea - physiopathology | Lung - physiopathology | Disease Progression | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Dyspnea - drug therapy | Aged | Drug Substitution | Health Status | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Lung diseases, Obstructive | Corticosteroids | Patient outcomes | Dosage and administration | Indacaterol | Drug therapy, Combination | Research | Drug therapy | Performance evaluation | Bronchodilation | Drugs | Medical research | Gold | Respiratory function | Acetylcholine receptors (muscarinic) | Control methods | Lung diseases | Clinical trials | Disease control | Patients | Primary care | Randomization | Dyspnea | Motivation | Obstructive lung disease | Clinical medicine | Safety | Respiration | glycopyrronium
Journal Article
International journal of chronic obstructive pulmonary disease, ISSN 1176-9106, 2019, Volume 14, pp. 249 - 260
Purpose: In contrast to randomized controlled trials (RCTs), changes in maintenance pharmacotherapy in clinical practice occur without a washout period. The... 
Indacaterol/glycopyrronium | Dyspnea | Lung function | COPD assessment test | FEV | TDI | FEV1 | VILANTEROL | INHALED CORTICOSTEROIDS | QVA149 | RISK | dyspnea | SALMETEROL-FLUTICASONE | OBSTRUCTIVE PULMONARY-DISEASE | lung function | RESPIRATORY SYSTEM | DUAL BRONCHODILATION | DOUBLE-BLIND | EXACERBATIONS | TRIPLE THERAPY | indacaterol/glycopyrronium | Salmeterol/fluticasone | Tiotropium
Journal Article